A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.
A combination of ticagrelor and aspirin improved the saphenous vein graft (SVG) patency rate 12 months after coronary artery bypass grafting (CABG) compared with aspirin alone, according to results of the DACAB* trial from China.
The incidence of cardiovascular events in the first year following a primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is comparable between patients given prasugrel and ticagrelor post-surgery, according to results of the PRAGUE-18* trial presented at AHA 2017.
Extreme fluctuations in systolic blood pressure (SBP) between doctor visits for an extended period of time was associated with an increased risk of death from any cause than those with less extreme variability in BP, suggests a study presented at the AHA Scientific Sessions 2017.
The incidence of clinically significant hematoma is similar in individuals with atrial fibrillation undergoing pacemaker or defibrillator surgery regardless of whether their direct oral anticoagulants (DOACs) are continued or interrupted perioperatively, results of the BRUISE CONTROL-2* trial show.
Gastric bypass may be an effective method of reducing blood pressure (BP) levels in obese patients with hypertension, according to findings of the GATEWAY* trial presented at the AHA** 2017 Scientific Sessions.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.